# Left Ventricular Non-Compaction Cardiomyopathy: The Tragedies & Trabeculations of the Architectural Cardiac Sponge

**Authors:** Noyan Ramazani, Brooke Ivey, Shudipan Chakraborty, Daniel Bishev, Michael DiCaro, Paul Duru, Ryan Shao, Aditi Singh

PMC · DOI: 10.3390/jcm15052023 · 2026-03-06

## TL;DR

Left-ventricular non-compaction is a rare heart condition causing abnormal heart structure, leading to serious complications like heart failure and arrhythmias.

## Contribution

The paper highlights the need for standardized diagnostic protocols and better understanding of LVNC's pathophysiology and genetics.

## Key findings

- LVNC affects 0.014% to 1.3% of the population and is often diagnosed using imaging techniques like TTE.
- LVNC can lead to heart failure, arrhythmias, and thromboembolic events, with a 3–4% lifetime prevalence of heart failure.
- There are currently no strict guidelines for LVNC screening, emphasizing the need for advanced clinical research and standardized protocols.

## Abstract

Left-ventricular non-compaction (LVNC) is a recently classified cardiomyopathy that involves abnormal trabeculations inside the left ventricle, most commonly located in the ventricular apex. There are 9 distinct types of non-compaction cardiomyopathy that can impact both the left and right ventricles with subtypes involving mostly pediatric patients with concurrent congenital heart disease (CHD), to individuals in late adult-staged ages. LVNC affects the population with an estimated range of incidence from 0.014% to 1.3% and the disease can be diagnosed with the utilization of imaging studies such as transthoracic echocardiography (TTE). LVNC can also impact and lead patients to develop heart failure with estimated prevalence that can reach to 3–4% during their lifetime. LVNC often leads to complications such as heart failure, arrhythmias, and thromboembolic events and without adequate medical management and pharmacological therapies this can progress and lead to worsening cardiac function, sudden cardiac arrest, and even death. There are no strict guidelines organized for screening and monitoring for LVNC in patients except with the inclusion of having a high suspicion in patients without other cardiac abnormalities. Thus, more advanced clinical research and the establishment of diagnostic protocols needs to be standardized in order to further investigate the causes, prognostic factors and therapeutic modalities of patients with LVNC. The field of LVNC cardiomyopathy is expanding but better understanding of the pathophysiology and genetic influence of this cardiac disease is vital for the precision treatment and personalized care of LVNC.

## Linked entities

- **Diseases:** Left-ventricular non-compaction (MONDO:0018901), heart failure (MONDO:0005252), congenital heart disease (MONDO:0005453)

## Full-text entities

- **Diseases:** LVNC (MESH:D056830), death (MESH:D003643), cardiac disease (MESH:D006331), cardiac arrest (MESH:D006323), cardiomyopathy (MESH:D009202), heart failure (MESH:D006333), thromboembolic (MESH:D013923), arrhythmias (MESH:D001145), CHD (MESH:D006330), cardiac abnormalities (MESH:D018376)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12986325/full.md

---
Source: https://tomesphere.com/paper/PMC12986325